Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors.
Buzon MJ, Erkizia I, Pou C, Minuesa G, Puertas MC, Esteve A, Castello A, Santos JR, Prado JG, Izquierdo-Useros N, Pattery T, Van Houtte M, Carrasco L, Clotet B, Ruiz L, Martinez-Picado J. Buzon MJ, et al. Among authors: esteve a. J Antimicrob Chemother. 2012 Jan;67(1):32-8. doi: 10.1093/jac/dkr433. Epub 2011 Oct 12. J Antimicrob Chemother. 2012. PMID: 21994909
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project].
Jaén A, Casabona J, Esteve A, Miró JM, Tural C, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Masabeu A, García I, Dorca E, Altès J, Navarro G, Podzamczer D, Villalonga C, Clotet B, Gatell JM; Grupo de Estudio PISCIS. Jaén A, et al. Among authors: esteve a. Med Clin (Barc). 2005 Apr 16;124(14):525-31. doi: 10.1157/13073938. Med Clin (Barc). 2005. PMID: 15847748 Spanish.
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
Llibre JM, Buzón MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutierrez M, Palmer S, Stevenson M, Blanco J, Martinez-Picado J, Clotet B. Llibre JM, et al. Among authors: esteve a. Antivir Ther. 2012;17(2):355-64. doi: 10.3851/IMP1917. Epub 2011 Sep 28. Antivir Ther. 2012. PMID: 22290239 Clinical Trial.
Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.
Massanella M, Esteve A, Buzón MJ, Llibre JM, Puertas MC, Gatell JM, Domingo P, Stevenson M, Clotet B, Martinez-Picado J, Blanco J; IntegRal Collaborative Group. Massanella M, et al. Among authors: esteve a. J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):152-60. doi: 10.1097/QAI.0b013e318289439a. J Acquir Immune Defic Syndr. 2013. PMID: 23392458
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, Esteve A, Boix J, Manzardo C, Miró JM, Gatell JM, Clotet B, Blanco J, Martinez-Picado J; MaraviBoost Collaborative Group. Puertas MC, et al. Among authors: esteve a. AIDS. 2014 Jan 28;28(3):325-34. doi: 10.1097/QAD.0000000000000066. AIDS. 2014. PMID: 24185044 Clinical Trial.
Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status.
Ferrer E, Curto J, Esteve A, Miro JM, Tural C, Murillas J, Segura F, Barrufet P, Casabona J, Podzamczer D; PISCIS Investigators. Ferrer E, et al. Among authors: esteve a. J Antimicrob Chemother. 2015 Dec;70(12):3332-8. doi: 10.1093/jac/dkv272. Epub 2015 Sep 25. J Antimicrob Chemother. 2015. PMID: 26410171
249 results